Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...

FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based ...

There is a simple discount patient access scheme for fedratinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The appraisal committee has prepared final draft guidance (FDG) on fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) and submitted it to NICE. The FDG ...

Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections.

These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources ...

This results in extramedullary hematopoiesis in other parts of the body, most notably the spleen, which is often enlarged. There are a number of therapeutic options to treat splenomegaly in ...

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous ...